EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.

ABSTRACT:

Background

Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population.

Methods

EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m² (arm A) or 125 mg/m² (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatmen

SUBMITTER: Biganzoli L 

PROVIDER: S-EPMC7405344 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature